Combination of serum microRNAs and ultrasound profile as predictive biomarkers of diagnosis and prognosis for papillary thyroid microcarcinoma

Zhang, Yanqing; Pan, Jiaqi; Xu, Desheng; Yang, Zhengyan; Sun, Jingxue; Sun, Lulu; Wu, Yanjiao; Qiao, Hong

doi:10.3892/or.2018.6776

Cited by 29 publications

(26 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To our best knowledge, miR-181b and miR-21 have not been investigated in plasma as possible biomarkers of PTC, although they have been found to be overexpressed in PTC tissue samples [14,18,25]. Furthermore, miR-21 was analyzed in serum samples and showed potential to become a diagnostic and prognostic marker of PTC [42,43]. We found a significant overexpression of plasma miR-222 in PTC compared to NG.…”

Section: Discussionmentioning

confidence: 70%

“…We chose to analyze miRNA expression in plasma samples because this bioliquid is prevented from clotting [40,41]. Certain studies have already shown changes in circulating miRNA expression in PTC patients [42][43][44]. Our findings suggest that these five miRNAs are overexpressed in PTC and spread from PTC cells to the bloodstream at detectable levels.…”

Section: Discussionmentioning

confidence: 78%

See 1 more Smart Citation

Plasma-Derived miRNA-222 as a Candidate Marker for Papillary Thyroid Cancer

Kondrotienė

Daukša

Pamedytytė

et al. 2020

IJMS

View full text Add to dashboard Cite

We analyzed five miRNA molecules (miR-221; miR-222; miR-146b; miR-21; miR-181b) in the plasma of patients with papillary thyroid cancer (PTC), nodular goiter (NG) and healthy controls (HC) and evaluated their diagnostic value for differentiation of PTC from NG and HC. Preoperative PTC plasma miRNA expression (n = 49) was compared with plasma miRNA in the HC group (n = 57) and patients with NG (n = 23). It was demonstrated that miR-221; miR-222; miR-146b; miR-21 and miR-181b were overexpressed in preoperative PTC plasma samples compared to HC (p < 0.0001; p < 0.0001; p < 0.0001; p < 0.0001; p < 0.002; respectively). The upregulation in tumor tissue of these miRNAs was consistent with The Cancer Genome Atlas Thyroid Carcinoma dataset. A significant decrease in miR-21; miR-221; miR-146b and miR-181b expression was observed in the plasma of PTC patients after total thyroidectomy (p = 0.004; p = 0.001; p = 0.03; p = 0.036; respectively). The levels of miR-222 were significantly higher in the preoperative PTC compared to the NG group (p = 0.004). ROC curve (receiver operating characteristic curve) analysis revealed miR-222 as a potential marker in distinguishing PTC from NG (AUC 0.711; p = 0.004). In conclusion; circulating miR-222 profiles might be useful in discriminating PTC from NG.

show abstract

Section: Discussionmentioning

confidence: 70%

Section: Discussionmentioning

confidence: 78%

Plasma-Derived miRNA-222 as a Candidate Marker for Papillary Thyroid Cancer

Kondrotienė

Daukša

Pamedytytė

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…Increasing attention has come to be attracted on the function of miRNAs as important biomarkers or mediators underlying the tumorigenesis of thyroid [24,25]. The current study mainly addressed the specific functions of miR-30d and molecular mechanisms by which miR-30d involved in the development of thyroid cancer, and our results presented that miR-30d could promote cell apoptosis through mediating USP22/SIRT1/FOXO3a/PUMA axis, thereby slowing down thyroid tumorigenesis ultimately (Fig.…”

Section: Discussionmentioning

confidence: 83%

WITHDRAWN: Contribution of microRNA-30d to the prevention of the thyroid cancer progression: mechanism and implications

Shao¹,

Zhang²,

Wang³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Thyroid cancer is a major endocrine tumor and represents an emerging health problem worldwide. MicroRNAs (miRNAs) have been addressed to be associated with the pathogenesis and progression of thyroid cancer. However, it remains largely unknown what functions miR-30d may exert on thyroid cancer. This study herein aimed to identify the functional significance and mechanism of miR-30d in the progression of thyroid cancer. Methods The expression of miR-30d and ubiquitin-specific protease 22 (USP22) in cancerous tissues of patients with thyroid cancer was measured using RT-qPCR and Western blot analysis. In response to the gain- or loss-of-function of miR-30d and USP22, cell apoptosis was evaluated by flow cytometry and TUNEL staining in combination with the measurement of apoptosis-related proteins. The interactions among miR-30d, USP22, SIRT1, FOXO3a and PUMA were explored using a series of assays, including dual-luciferase reporter gene assay, Co-IP and ChIP assay. The effects of miR-30d and USP22 on thyroid tumorigenesis were finally validated in vivo. Results MiR-30b presented aberrant low expression in thyroid cancer tissues and this low expression correlated with poor prognosis of thyroid cancer patients. miR-30d promoted apoptosis of thyroid cancer cells through targeting USP22, an up-regulated gene in thyroid cancer. USP22 could enhance the stability of SIRT1 by inducing deubiquitination which consequently contributed to FOXO3a deacetylation-induced PUMA repression. It was verified that this regulatory mechanism was responsible for the pro-apoptotic effect of miR-30d by the in vivo tumorigenicity assay. Conclusion To conclude, the progression of thyroid cancer can be suppressed by miR-30d-mediated inhibition of USP22, provides a promising therapeutic target for thyroid cancer treatment.

show abstract

“…Seven articles used benign thyroid nodule (BTN) patients as controls, and two articles 14,15 using both BTN patients and healthy people as controls. One article 16 studied papillary thyroid micro carcinoma (PTMC) patients, and other eight articles studied PTC patients. six articles were prospective studies, and three articles 5,15,17 were retrospective studies.…”

Section: Resultsmentioning

confidence: 99%

Diagnostic value of circulating microRNAs in thyroid carcinoma: A systematic review and meta‐analysis

Tian

Zhou

et al. 2020

Clinical Endocrinology

View full text Add to dashboard Cite

Background and objective Thyroid cancer (TC) is the most common endocrine system tumour. Several studies had revealed the potential of circulating microRNAs (miRNAs) as novel biomarkers for the diagnosis of TC. The purpose of this meta‐analysis is to summarize published studies and evaluate the diagnostic accuracy of circulating miRNAs in TC detection. Methods In this meta‐analysis, we systematically searched three databases: PubMed, EMBASE and Cochrane Library. We used the bivariate mixed‐effects regression model to calculate the pooled diagnostic parameters and conduct the summary receiver operator characteristic curve (SROC). All calculations were performed using stata software. Results Thirty‐five studies from 9 articles, including 663 TC patients, 519 patients with benign thyroid nodules (BTNs), and 84 healthy controls were included in this meta‐analysis. The pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR) and area under the SROC curve (AUC) were 0.81 (95% CI 0.75‐0.86), 0.81 (95% CI 0.75‐0.86), 4.3 (95% CI 3.2‐5.6), 0.24 (95% CI 0.18‐0.31), 18 (95% CI 12‐28) and 0.88 (95% CI 0.85‐0.90), respectively in BTN controls, and 0.81 (95% CI 0.75‐0.86), 0.85 (95% CI 0.75‐0.91), 5.3 (95% CI 3.3‐8.7), 0.23 (95% CI 0.18‐0.29), 24 (95% CI 14‐39), 0.89 (95% CI 0.86‐0.91) in healthy controls. The subgroup analysis found that multiple miRNA assays had higher diagnostic accuracy than single miRNA assays with sensitivity of 0.88, specificity of 0.89 and AUC of 0.94. Conclusion Circulating miRNAs have good values to diagnose TC and distinguish TC patients from BTN patients. MiRNAs can assist in the diagnosis of malignancy and avoid unnecessary surgery. In summary, circulating miRNAs should be added to our current clinical tools.

show abstract

Combination of serum microRNAs and ultrasound profile as predictive biomarkers of diagnosis and prognosis for papillary thyroid microcarcinoma

Cited by 29 publications

References 74 publications

Plasma-Derived miRNA-222 as a Candidate Marker for Papillary Thyroid Cancer

Plasma-Derived miRNA-222 as a Candidate Marker for Papillary Thyroid Cancer

WITHDRAWN: Contribution of microRNA-30d to the prevention of the thyroid cancer progression: mechanism and implications

Diagnostic value of circulating microRNAs in thyroid carcinoma: A systematic review and meta‐analysis

Contact Info

Product

Resources

About